Search research articles
Contact Us
Filters
Showing results (441-450 of 738) with videos related to
Page
of 74
Sort By:
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Ana Oaknin, Bradley J Monk, Ignace Vergote, et al.
Gynecologic Oncology
|
March 8, 2025
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
Allan Covens, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology
|
May 12, 2026
Endometriosis and ovarian cancer risk
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
Molecular Cancer Therapeutics
|
August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Future Oncology (London, England)
|
June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Thomas J Herzog, John L Hays, Joyce N Barlin, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Journal of Comparative Effectiveness Research
|
December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
Page
of 74
Search research articles
Search
Showing results (441-450 of 738) with videos related to
Sort By:
Page
of 74
The Lancet. Oncology
|
June 22, 2014
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
Ana Oaknin, Bradley J Monk, Ignace Vergote, et al.
Gynecologic Oncology
|
March 8, 2025
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
Allan Covens, Helen Q Huang, Bradley J Monk, et al.
Gynecologic Oncology
|
May 12, 2026
Endometriosis and ovarian cancer risk
Giorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
Molecular Cancer Therapeutics
|
August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)
Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Future Oncology (London, England)
|
June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Thomas J Herzog, John L Hays, Joyce N Barlin, et al.
Clinical Therapeutics
|
July 17, 2024
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Bradley J Monk, Ignacio Romero, Whitney Graybill, et al.
Journal of Comparative Effectiveness Research
|
December 6, 2024
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, et al.
Page
of 74